| Literature DB >> 29684067 |
Meri I E Uusi-Mäkelä1, Harlan R Barker2, Carina A Bäuerlein1, Tomi Häkkinen3, Matti Nykter3, Mika Rämet1,4,5.
Abstract
CRISPR-Cas9 technology is routinely applied for targeted mutagenesis in model organisms and cell lines. Recent studies indicate that the prokaryotic CRISPR-Cas9 system is affected by eukaryotic chromatin structures. Here, we show that the likelihood of successful mutagenesis correlates with transcript levels during early development in zebrafish (Danio rerio) embryos. In an experimental setting, we found that guide RNAs differ in their onset of mutagenesis activity in vivo. Furthermore, some guide RNAs with high in vitro activity possessed poor mutagenesis activity in vivo, suggesting the presence of factors that limit the mutagenesis in vivo. Using open access datasets generated from early developmental stages of the zebrafish, and guide RNAs selected from the CRISPRz database, we provide further evidence for an association between gene expression during early development and the success of CRISPR-Cas9 mutagenesis in zebrafish embryos. In order to further inspect the effect of chromatin on CRISPR-Cas9 mutagenesis, we analysed the relationship of selected chromatin features on CRISPR-Cas9 mutagenesis efficiency using publicly available data from zebrafish embryos. We found a correlation between chromatin openness and the efficiency of CRISPR-Cas9 mutagenesis. These results indicate that CRISPR-Cas9 mutagenesis is influenced by chromatin accessibility in zebrafish embryos.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29684067 PMCID: PMC5912780 DOI: 10.1371/journal.pone.0196238
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1In vitro and in vivo CRISPR-Cas9 mutagenesis efficiencies do not correlate for all genes.
a) An in vitro digestion assay shows that sgRNAs differ in their efficiencies. Below the gene name, + and - indicate the presence or absence of Cas9 protein in the reaction. On the right the wild type (wt) and the mutant products are indicated. b) The in vivo CRISPR-Cas9 mutagenesis visualized for ca6, cxcr2 and pycard with a heteroduplex mobility assay, with the wild type (wt) and the mutant products indicated. 5 embryos were collected per sample at 8hpf.
Fig 2Onset of mutagenesis differs between sgRNAs.
Heteroduplex mobility assay to demonstrate the onset of mutagenesis using high efficiency guide RNAs targeting three different genes with different gene expression patterns in early development. Embryos were collected at timepoints 1, 2, 3, 4, 6hpf (15–20 embryos per group). The gene name above the gel image indicates CRISPR-Cas9 injected embryos and control indicates uninjected controls. The legend on the side indicates the positions of wt (wild type) and mutant bands in the gel. Red arrows indicate the point at which first mutations can be detected.
Fig 3Relationship of transcript levels in early development and low mutagenesis efficiency.
Pie charts of the RNA-seq data corresponding to graphs in S1 Fig. a) Number of transcripts for the genes resistant to (left) or permissive (right) for mutagenesis between the oblong sphere and the 15-somite stage (Fischer’s exact test; not significant). 0.5 RPKM (Reads per Kilobase of transcript per Million mapped reads) was used as a limit for low expression. b) The number of genes resistant (left) or permissive (right) for CRISPR-Cas9 mutagenesis in which the number of transcripts is increased or decreased between the oblong sphere-stage and 50% epiboly (around the MZT) (Fischer’s exact test; not significant).
Correlation between mutagenesis efficiency and gene expression at different developmental stages during early development.
n = 209.
| Developmental stage | Spearman correlation | p-value |
|---|---|---|
| 64-cell | 0.190 | 0.006* |
| oblong-sphere | 0.227 | 0.001* |
| 50%-epiboly | 0.187 | 0.007* |
| 15-somite | 0.210 | 0.002* |
| 36hpf | 0.230 | 0.001* |
| 48hpf | 0.182 | 0.008* |
| 60hpf | 0.188 | 0.006* |
| 72hpf | 0.131 | 0.058 |
Correlation between mutagenesis efficiency and chromatin features at different developmental stages and timepoints.
| Chromatin feature | n | Developmental stage/Timepoint | Spearman correlation | p-value |
|---|---|---|---|---|
| Exon methylation | 263 | 1-cell | 0.115 | 0.063 |
| Mid blastula transition | 0.107 | 0.084 | ||
| H3K4me3 | 47 | 75–80% epiboly | 0.263 | 0.074 |
| Chromatin accessibility | 263 | 4hpf | 0.182 | 0.003* |